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ABSTRACT
Objectives: To synthesize novel pyrazole derivatives and their evaluation for anti-inflammatory activity. 
Methods: The synthesis of chalcone (1) was carried out by using Claisen-Schmidt condensation. which on further cyclization with thiosemicarbazide 
gives the substituted 3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothoic acid amide (2), further reaction with different aldehydes yield title compounds 
(3). Using this scheme 8 compounds were synthesized which further have been evaluated for anti-inflammatory activity by egg-albumin induced paw 
edema.
Results: All the synthesized compounds have been supported by spectral analysis. The anti-inflammatory activity of synthesized compounds was 
compared with standard anti-inflammatory agent Diclofenac sodium.
Conclusion: Compound-8, compound-2 and compound-3 showed greater anti-inflammatory activity due to the presence of alkene and electron 
withdrawing groups (Cl and NO2). 
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INTRODUCTION
Pyrazole chemically known as 1, 2-diazole has become a popular topic 
due to its manifold uses. The chemistry of pyrazole and its derivatives 
are particularly interesting because of their potential application in 
medicinal chemistry as antitumor [1], antibacterial [2], antifungal [3], 
antiviral [4], antiparasitic [5], anti-tubercular [6], and insecticidal 
agents [7]. Some of these compounds have also anti-inflammatory [8], 
anti-diabetic [9], anesthetic [10], and analgesic [11] properties. 
Moreover, chalcones have played a crucial part in the development of 
theory of heterocyclic compounds, and also they used extensively in 
organic synthesis. A classical synthesis of these compounds involves the 
base-catalyzed claisen-schmidt reaction of ketones and aldehydes to 
give α, β-unsaturated ketones (chalcones), which undergo a subsequent 
reaction with thiosemicarbazide affording pyrazoles. Inflammation 
(Latin, inflammo, “I ignite, set alight”) is part of the complex biological 
response of vascular tissues to harmful stimuli, such as pathogens, 
damaged cells, or irritants. The classical signs of acute inflammation 
are pain, heat, redness, swelling, and loss of function. Inflammation is a 
protective attempt by the organism to remove the injurious stimuli and 
to initiate the healing process.
METHODS
General
All the chemicals were obtained from SD Fine chem. Limited (Mumbai). 
All the glassware is of borosilicate grade. Melting points were 
determined in open capillaries and were uncorrected. The melting 
point of an organic compound was determined by Thiel’s melting 
point apparatus. The purity of the compounds was ascertained by thin-
layer chromatographic (TLC) on silica gel-G plate. TLC is an important 
method for synthetic chemistry to infer the formation of the compound 
based on the Rf value since different compound will have different Rf 
values. It also helps in the confirming the reaction.
Fourier transform infrared (FT-IR) spectra were taken in KBr on a thermo 
nicolet nexus 670 spectrophotometer. 1HNMR spectra were recorded on 
BRUKER AVANCE 300MHz spectrophotometer in CDCl3 with TMS as an 
internal standard. The chemical shift values are in delta (ppm). Mass 
spectra were recorded on Polaris Q apparatus (thermo electron) and the 
fragmentations were obtained by electronic impact (EI). The data are 
given as mass to charge ratio (m/z) and nominal masses were used for 
the calculation of molecular weights of the synthesized products.
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Step-1: Synthesis of chalcone (1)
Equimolar quantity of benzaldehyde (0.01 mol) (1.06 ml) and 
acetophenone (0.01 mol) (1.2 ml) were placed in 30 mL of ethanol. 
The mixture was allowed to stir for 15 minutes. A 10 mL 40% aqueous 
potassium hydroxide solution was slowly added dropwise to the 
reaction flask via a dropping funnel. The reaction solution was allowed 
to stir at room temperature for 1.5 hrs. A precipitate formed was then 
collected by filtration.
Step-2: Synthesis of 3, 5-diphenyl-4, 5-dihydro-pyrazole-1-
carbothoic acid amide (2)
A mixture of chalcones (1) (0.01 mol) (2.08 g), thiosemicarbazide (0.01 
mol) (0.91 g), and KOH (0.0025 mol) (1.4 g) was refluxed in ethanol 
(30 mL) for 6 hrs. The completion of is monitored by TLC. The solution 
was poured into ice-water. The precipitate was filtered and crystallized 
from methanol.
Step-3: Synthesis of Substituted 3, 5-diphenyl-4, 5-dihydro-
pyrazole-1-carbothioic acid benzylideneamide (3)
A mixture of different aldehyde (0.05 mol) and glacial acetic acid (18 ml) 
is refluxed in RBF (100 ml) capacity, 0.05 moles of 3, 5-Diphenyl-4, 
5-dihydro-pyrazole-1-carbothoic acid amide (2) is added through the 
neck and mixture is refluxed for 30 minutes, the completion of reaction 
is known by TLC. Then, the solution is cooled in the ice-salt bath with 
stirring. The separated product is filtered, washed with water and 
recrystallized with ethanol.
3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 
benzylideneamide (CP-1)
Steps 1 and 2 products were dissolved in glacial acetic acid and 
following the above general procedure desired compound was obtained 
in 62.33% yield, m.p. > 300°C, IR (KBr): 1509 cm−1 (-C=N), 1444 cm−1 
(C=S), and 3160 cm−1 (-CH-Ar), 1H NMR (CDCl3): 2.2 s (-CH2), 8.2 s 
(-CH=N), 3.8 s (-CH) and 6.8-7.8 m (Ar-H), EI-MS m/e: M+ ion peak 368.
3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 4-chloro-
benzylideneamide (CP-2)
73.69% yield, m.p. >300°C, IR(KBr): 1593 cm−1 (-C=N), 1444 cm−1 (C=S), 
837cm−1 (C-Cl) and 3163 cm−1 (-CH-Ar), 1H NMR (CDCl3): 1.9 s (-CH2), 8.0s 
(-CH=N), 3.8 s (-CH) and 7.2-7.9 m (Ar-H), EI-MS m/e: M+ ion peak 402.
3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 4-nitro-
benzylideneamide (CP-3)
61.04% yield, m.p. >300°C, IR (KBr): 1561 cm−1(-C=N), 1469 cm−1 (C=S), 
1469 cm−1 (C-NO2) and 3059 cm−1 (-CH-Ar), 1H NMR (CDCl3): 2.0 s 
(-CH2), 8.1 s (-CH=N), 3.8 s (-CH) and 7.2-7.7 m (Ar-H), EI-MS m/e: M+ 
ion peak 413.
3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 4-hydroxy-
benzylideneamide (CP-4)
77.41% yield, m.p. >300°C, IR (KBr): 1568 cm−1 (-C=N), 1465 cm−1 
(C=S), 3483 cm−1 (C-OH, phenolic) and 3049 cm−1 (-CH-Ar), 1H NMR 
(CDCl3): 2.1s (-CH2), 8.0s (-CH=N), ‘3.9s(-CH) and 6.79-7.9 m (Ar-H), EI-
MS m/e: M+ ion peak 384.
3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 4-hydroxy-
3-methoxy-benzylideneamide (CP-5)
70% yield, m.p. > 300°C, IR (KBr): 1599 cm−1 (-C=N), 1447 cm−1 (C=S), 
3483 cm−1 (C-OH, phenolic), 2931 cm−1 (-OCH3) and 3026 cm−1 (-CH-Ar), 
1H NMR (CDCl3): 2.0 s (-CH2), 8.2 s (-CH=N), 3.9 s (-CH) and 6.8-7.9 m 
(Ar-H), EI-MS m/e: M+ ion peak 414.
3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 
4-dimethylamino-benzylideneamide (CP-6)
63.02% yield, m.p. >300°C, IR (KBr): 1568 cm−1 (-C=N), 1468 cm−1 
(C=S), 1164 cm−1 (-N(CH3)2) and 3049 cm−1 (-CH-Ar), 1H NMR (CDCl3): 
2.1s (-CH2), 8.0s (-CH=N), 3.9s (-CH) and 6.9-7.9 m (Ar-H), EI-MS m/e: 
M+ ion peak 411.
3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 
ethylideneamide (CP-7)
65.36% yield, m.p. > 300°C, IR(KBr): 1599 cm−1 (-C=N), 1448 cm−1 
(C=S), 1493 cm−1 (-CH3) and 2940 cm−1 (-CH-Ar), 1H NMR (CDCl3): 1.9s 
(-CH2), 8.0s (-CH=N), 3.9s (-CH) and 6.8-7.8m (Ar-H), EI-MS m/e: M+ 
ion peak 306.
3, 5-diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid but-2-
enylideneamide (CP-8)
54.27% yield, m.p. > 300°C, IR (KBr): 1590 cm−1 (-C=N), 1385 cm−1 
(C=S), 1455 cm−1 (-CH3) and 2950 cm−1 (-CH-Ar), 1H NMR (CDCl3): 1.9s 




Male or female Wistar-albino rats with a body weight between 100 
and 150 g are used. They were acclimated to laboratory conditions for 
7 days before commencement of experiments and were allowed free 
access to standard drug pellet diet and water ad libitum. The animals 
are starved overnight.
Table 1: Group of animals, drugs and their dosage forms
Groups Sample Dose
Group-1 Control (5% gum acacia suspension) 10 ml/kg
Group-2 Standard (diclofenac sodium) 5 mg/kg
Group-3 Compound-1 100 mg/kg
Group-4 Compound-2 100 mg/kg
Group-5 Compound-3 100 mg/kg
Group-6 Compound-4 100 mg/kg
Group-7 Compound-5 100 mg/kg
Group-8 Compound-6 100 mg/kg
Group-9 Compound-7 100 mg/kg
Group-10 Compound-8 100 mg/kg
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The grouping of animals according to the type of compound and its 
dose are represented in Table 1.
Experimental procedure for fresh egg white induced paw edema 
method [12]
To ensure uniform hydration, the rats receive the test drug at a dose 
level of 100 mg/kg body weight suspended in 5% acacia solution. 
30 minutes later, the rats are challenged by a subcutaneous injection 
of 0.05 ml of 1% solution of egg albumin into the plantar side of the 
left hind paw. The paw is marked with ink at the level of the lateral 
malleolus and immersed in mercury up to this mark. The paw volume is 
measured with plethysmometer immediately after injection, again after 
1 hr, 2 hrs, and 3 h and 5 hrs % inhibition was calculated by following 
a formula.
%Inhibition = ([control−test]/control) × 100
The values are calculated by Dunnett method by comparing all the 
compounds with control in One-way Analysis of Variance (ANOVA) and 
are expressed in Mean ± SEM.
The physical data of synthesized compounds are given in table 2
Table 2: Physical data of synthesized compounds







3, 5-Diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid benzylideneamide
C23H19N3S 369.4821 62.33
CP-2






3, 5-Diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 4-hydroxy-benzylideneamide
C23H18N3OS 385.1249 77.41
CP-5
3, 5-Diphenyl-4, 5-dihydro-pyrazole-1-carbothioic acid 4-hydroxy-3-methoxy-benzylideneamide
C24H21N3O2S 415.5074 70
(Contd...)
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Fig. 3: Bar diagram with mean and standard error of mean at 
1 hr-5 hrs
RESULTS
The physical data of synthesized compounds are given in Table 2. 
The results obtained from the synthesized compounds with a dose of 
100 mg/kg confirmed that maximum activity was obtained when R 
was substituted by alkene (compound-8) with 73.72% inhibition, when 
R was substituted by a chlorine group (compound-2) with 70.80% 
inhibition; R was substituted by –NO2 group (compound-3) with 
70.80% inhibition, R was substituted by alkane group (compound-7) 
with 66.83% inhibition, R was substituted by benzaldehyde 
(compound-1) with 49.27% inhibition, R was substituted by –OH group 
(compound-4) with 36.86% inhibition, R was substituted by –N (CH3)2 
group (compound-6) with 32.85% inhibition and R was substituted 
by vanillin group (compound-5) with 26.28% inhibition. Based on 
the “p” value, compound-8, 2 and 3 showed higher significance from 
1 hr to 5 hrs when compared to control. It was found that the electron 
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withdrawing groups and alkene containing synthesized compounds 
enhanced the anti-inflammatory activity. The effect of Diclofenac 
sodium and test compounds on paw thickness shown in the Fig. 1 and 
percentage inhibition of paw thickness shown in Fig. 2 and comparison 
data for significance of synthesized compounds versus control given in 
Table 3 and bar diagram shown in Fig. 3.
CONCLUSION
The synthesized novel pyrazole derivatives were subjected to in 
vivo anti-inflammatory evaluation. Anti-inflammatory activity of the 
synthesized compounds was evaluated by egg-albumin induced rat paw 
edema method. The activity was studied at the dose levels of 100 mg/kg 
body weight, and their effects were measured at 1, 2, 3, and 5 hrs.
The paw volume of the rat in inhibiting inflammation by the 
synthesized compounds at different time intervals is measured by 
mercury displacement method. The anti-inflammatory studies revealed 
that all the synthesized novel pyrazole derivatives showed significant 
anti-inflammatory activity when compared with that of standard drug 
diclofenac sodium. CP-8, CP-2 and CP-3 showed greater Pharmacological 
activity due to the presence of alkene and electron withdrawing 
groups Cl, NO2 respectively. Whereas, CP-5, CP-6, CP-4, CP-1, and CP-7 
showed mild to moderate activity. Therefore, further studies required 
for pharmacologically more potent compounds in these series.
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